Context-Specific Efficacy of Apalutamide Therapy in Preclinical Models of <i>Pten</i>-Deficient Prostate Cancer

Context-Specific Efficacy of Apalutamide Therapy in Preclinical Models of <i>Pten</i>-Deficient Prostate Cancer

Significant improvements with apalutamide, a nonsteroidal antiandrogen used to treat patients suffering from advanced prostate cancer (PCa), have prompted evaluation for additional indications and therapeutic development with other agents; however, persistent androgen receptor (AR) signaling remains...

Full description

Bibliographic Details
Main Authors: Marco A. De Velasco, Yurie Kura, Naomi Ando, Noriko Sako, Eri Banno, Kazutoshi Fujita, Masahiro Nozawa, Kazuhiro Yoshimura, Kazuko Sakai, Kazuhiro Yoshikawa, Kazuto Nishio, Hirotsugu Uemura
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Cancers
Subjects:
prostate cancer
androgen receptor
preclinical efficacy
apalutamide
castration resistance
PTEN
Online Access:https://www.mdpi.com/2072-6694/13/16/3975

Internet

https://www.mdpi.com/2072-6694/13/16/3975

Similar Items